DEPLOYDatabase

Partnership

Stryker acquires Wright Medical Group

Stryker acquired Wright Medical Group N.V. for approximately USD 4 billion, enhancing its trauma and extremities portfolio. The FTC required divestment of Stryker's total ankle replacement assets and Wright's finger joint implant assets as a condition of approval. The acquisition was completed on November 11, 2020

investment · Concluded · operating


Machine-readable surfaces

a660ac5e-8e61-4199-8069-b443416de6c4
Type
investment
Status
Concludedoperating
Announced
2019-11-04
6.8 years ago
Start
2020-11-11
5.8 years ago
Active for
5.8 years

Who’s involved

Strykerinvestor partner

Stryker Corporation (NYSE: SYK) is one of the [World](/companies/world-labs)'s largest medical technology companies, headquartered in Kalamazoo, Michigan, with $25B in 2025 revenue and approximately 56,000 employees. The company's Mako SmartRobotics platform is the leading robotic orthopedic surgery system, with record Mako installations in 2024 for hip and knee replacements, and the next-generation Mako showcased at AAOS 2025 including the new Mako Shoulder application.

HQKalamazoo, MI, USAstryker.com4 partnerships

Wright Medical Group N.V. (formerly NASDAQ: WMGI) was a global medical device company specializing in upper and lower extremities (shoulder, elbow, wrist, hand, foot, ankle) and biologics, headquartered in Memphis, Tennessee. Founded in 1950, the company merged with Tornier N.V. in 2015 in a USD 3.3 billion tax inversion deal and was acquired by [Stryker](/companies/stryker) in November 2020 for approximately USD 4 billion. Wright Medical also developed preoperative planning technology and had a robotics program through its acquisition of IMASCAP

HQMemphis, TN, USAwright.com1 partnerships

Most-frequent partners

Related partnerships

Recent partnerships of the same kind

Sources (1)

  1. https://www.stryker.com/us/en/about/news/2020/stryker-completes-acquisition-of-wright-medical.html

Deploy Watch

Track this partnership.

We notify you when the status changes against primary-source evidence, expansion is verified, or the partnership is terminated.